Skip to main content
. 2024 Aug 27;67(3):225–232. doi: 10.33160/yam.2024.08.009

Table 2.  Demographics and laboratory findings of the study population.

No. of patients 1816
Age, y, median (IQR) 69.5 (33)
Female sex, n (%) 982 (54.1)
qSOFA score median (IQR) 1 (2)
SOFA score median (IQR) 4 (7)
APACHE II score median (IQR) 19 (15)
Lactate median (IQR) 2,3 (2.28)
Length of stay in i care (day) (IQR) 4 (5)
The need for mechanical ventilation n (%) 612 (33.7)
In-hospital mortality n (%) 374 (20.6)
6-month mortality n (%) 796 (43.8)
Diagnosis n (%) 1816 (100)
 Sepsis and septic shock 434 (23.9)
 Poisoning 338 (18.6)
 Cerebrovascular disease 295 (16.2)
 Respiratory failure 154 (8.5)
 ROSC after CA 117 (6.4)
 Acute renal failure 97 (5.3)
 Diabetic ketoacidosis 94 (5.2)
 Decompensated heart failure 92 (5.1)
 Gastrointestinal hemorrhage 83 (4.6)
 Pulmonary thromboembolism 34 (1.9)
 Status epilepticus 31 (1.7)
 Liver failure 20 (1.1)
 Anaphylactic shock 14 (0.8)
 Multiple trauma 12 (0.7)
 Eclampsia 1 (0.1)
Resume n (%) 1816 (100)
 Hypertension 780 (42.9)
 Diabetes mellitus 596 (32.8)
 Coronary artery disease 378 (20.8)
 Cerebrovascular disease 160 (8.8)
 Heart failure 283 (15.6)
 COPD / Asthma 223 (12.3)
 Alzheimer’s 84 (4.6)
 Cancer 60 (3.3)
 Chronic renal disease 53 (2.9)
 Chronic liver disease 16 (0.9)
 Hyperlipidemia 45 (2.5)
 Epilepsy 34 (1.9)

APACHE, Acute Physiology and Chronic Health Evaluation; COPD, Chronic Obstructive Pulmonary Disease; ROSC after CA, return of spontaneous circulation after cardiac arrest; SOFA, Sequential Organ Failure Assessment; qSOFA, quick sequential organ failure assessment.